Overview

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: This partially randomized phase III trial is studying how well combination chemotherapy works in treating young patients with relapsed or refractory acute lymphoblastic leukemia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Cancer and Leukaemia Group
Treatments:
Asparaginase
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Idarubicin
Methotrexate
Mitoxantrone
Pegaspargase
Vincristine
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of acute lymphoblastic leukemia (ALL) meeting 1 of the following criteria:

- In first relapse after treatment

- Has not yet received chemotherapy or radiotherapy for the first relapse

- Primary refractory disease

- No mature B-cell ALL

- Meets criteria for one of the following risk groups:

- Standard-risk disease: non-T-cell or T-cell ALL with late isolated extramedullary
relapse

- Intermediate-risk disease: non-T-cell ALL with early isolated extramedullary
relapse or combined marrow and extramedullary relapse; non-T-cell ALL with late
combined marrow and extramedullary relapse or isolated marrow relapse; or T-cell
ALL with early isolated extramedullary relapse

- High-risk disease: non-T-cell ALL with very early isolated extramedullary
relapse, combined marrow and extramedullary relapse, or isolated marrow relapse;
non-T-cell ALL with early isolated marrow relapse; T-cell ALL with very early
isolated extramedullary relapse, combined marrow and extramedullary relapse, or
isolated marrow relapse; T-cell ALL with early combined marrow and extramedullary
relapse or isolated marrow relapse; or T-cell ALL with late combined marrow and
extramedullary relapse or isolated marrow relapse

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior bone marrow transplant